A jury in Delaware federal court found Boston Scientific's SYNERGY stents were derived from information given to the company executives both in person at a conference and again via email exchanges.
February 06, 2023 at 03:00 PM
3 minute read
The original version of this story was published on Texas Lawyer
Attorneys from firms in Dallas and Houston secured a $42 million jury verdict on patent infringement for a state university and bioengineering company against Boston Scientific Corp.
The trial in the U.S. District Court for the District of Delaware concluded with plaintiff attorneys prevailing on patent infringement claims related to a biodegradable polymer fiber drug delivery system that was incorporated into Massachusetts-based Boston Scientific’s SYNERGY branded coronary stents.
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
Join the Mendocino County District Attorney s Office and work in Mendocino County home to redwoods, vineyards and picturesque coastline. ...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Schematic exhibits from the Joint Claim Construction Brief in Board of Regents UTS v Boston Scientific. Source: Court filing docket #245.
